RxSight price target raised by $5 at Needham, here’s why

Needham analyst David Saxon raised the firm’s price target on RxSight to $35 from $30 and keeps a Buy rating on the shares following an ophthalmology survey with 35 respondents to get updated checks on key vision care segments. Based on the firm’s survey work, the firm believes RxSight should continue to gain IOL market share, driven by continued adoption by new accounts and increasing utilization in existing accounts, the analyst tells investors.